Prognostic impact of gene expression-based classification for neuroblastoma

Journal of Clinical Oncology

Volumn 28, Issue 21, 2010, Pages 3506-3515

  Oberthuer, André ^a   Hero, Barbara ^a   Berthold, Frank ^a   Juraeva, Dilafruz ^a   Faldum, Andreas ^a   Kahlert, Yvonne ^a   Asgharzadeh, Shahab ^a   Seeger, Robert ^a   Scaruffi, Paola ^a   Tonini, Gian Paolo ^a   Janoueix Lerosey, Isabelle ^a   Delattre, Olivier ^a   Schleiermacher, Gudrun ^a   Vandesompele, Jo ^a   Vermeulen, Joëlle ^a   Speleman, Frank ^a   Noguera, Rosa ^a   Piqueras, Marta ^a   Bénard, Jean ^a   Valent, Alexander ^a   Avigad, Smadar ^a   Yaniv, Isaac ^a   Weber, Axel ^a   Christiansen, Holger ^a   Grundy, Richard G ^a   Schardt, Katharina ^a   Schwab, Manfred ^a   Eils, Roland ^a   Warnat, Patrick ^a   Kaderali, Lars ^a   Simon, Thorsten ^a   DeCarolis, Boris ^a   Theissen, Jessica ^a   Westermann, Frank ^a   Brors, Benedikt ^a   Fischer, Matthias ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

144 GENE PREDICTION ANALYSIS FOR MICROARRAYS CLASSIFIER; ADOLESCENT; ADULT; ARTICLE; BELGIUM; CANCER RISK; CHILD; CLASSIFIER; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEATH; EVENT FREE SURVIVAL; FOLLOW UP; FRANCE; GENE EXPRESSION PROFILING; GENETIC RISK; GERMANY; HUMAN; INFANT; ISRAEL; ITALY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; NEWBORN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SPAIN; UNITED KINGDOM; UNITED STATES; CLASSIFICATION; GENETICS; MORTALITY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; GENE EXPRESSION PROFILING; HUMANS; INFANT; INFANT, NEWBORN; NEUROBLASTOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 77955287153     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.3367     Document Type: Article

References (31)

1. Maris JM, Hogarty MD, Bagatell R, et al: Neuroblastoma. Lancet 369:2106-2120, 2007 (Pubitemid 46935947)
2. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993 (Pubitemid 23228250)
3. Evans AE, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma: Children's Cancer Study Group A. Cancer 27:374-378, 1971
4. London WB, Castleberry RP, Matthay KK, et al: Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23:6459-6465, 2005 (Pubitemid 46190236)
5. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124, 1984 (Pubitemid 14106392)
6. Shimada H, Ambros IM, Dehner LP, et al: The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364-372, 1999 (Pubitemid 29327594)
7. Brodeur GM, Fong CT, Morita M, et al: Molecular analysis and clinical significance of N-myc amplification and chromosome 1p monosomy in human neuroblastomas. Prog Clin Biol Res 271:3-15, 1988
8. Attiyeh EF, London WB, Mossé YP, et al: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243-2253, 2005 (Pubitemid 41697287)
9. Cohn SL, Pearson AD, London WB, et al: The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 27:289-297, 2009
10. Look AT, Hayes FA, Nitschke R, et al: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311:231-235, 1984 (Pubitemid 14087665)
11. Yamamoto K, Ohta S, Ito E, et al: Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: Cohort study in seven prefectures in Japan. J Clin Oncol 20:1209-1214, 2002 (Pubitemid 34177426)
12. Schilling FH, Spix C, Berthold F, et al: Neuroblastoma screening at one year of age. N Engl J Med 346:1047-1053, 2002 (Pubitemid 34984618)
13. Woods WG, Gao RN, Shuster JJ, et al: Screening of infants and mortality due to neuroblastoma. N Engl J Med 346:1041-1046, 2002 (Pubitemid 34984617)
14. Hero B, Simon T, Spitz R, et al: Localized infant neuroblastomas often show spontaneous regression: Results of the prospective trials NB95-S and NB97. J Clin Oncol 26:1504-1510, 2008
15. Fischer M, Spitz R, Oberthür A, et al: Risk estimation of neuroblastoma patients using molecular markers. Klin Padiatr 220:137-146, 2008
16. Oberthuer A, Berthold F, Warnat P, et al: Customized oligonucleotide microarray gene expressionbased classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 24:5070-5078, 2006 (Pubitemid 46631411)
17. Ambros PF, Ambros IM: Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37:492-504, 2001 (Pubitemid 33101388)
18. Tibshirani R, Hastie T, Narasimhan B, et al: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99:6567-6572, 2002 (Pubitemid 34526173)
19. Collett D: Strategy for model selection, in: Modelling Survival Data in Medical Research. London, United Kingdom, Chapman & Hall, 1994, pp 78-83
20. Simon T, Spitz R, Faldum A, et al: New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 26:791-796, 2004 (Pubitemid 40019177)
21. Oberthuer A, Theissen J, Westermann F, et al: Molecular characterization and classification of neuroblastoma. Future Oncol 5:625-639, 2009
22. Brodeur GM: Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3:203-216, 2003
23. Maris JM: The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 17:7-13, 2005
24. Vermeulen J, De Preter K, Naranjo A, et al: Predicting outcomes for children with neuroblastoma using a multigene-expression signature: A retrospective SIOPEN/COG/GPOH study. Lancet Oncol 10:663-671, 2009
25. Asgharzadeh S, Pique-Regi R, Sposto R, et al: Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 98:1193-1203, 2006 (Pubitemid 44390990)
26. Ohira M, Oba S, Nakamura Y, et al: Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 7:337-350, 2005 (Pubitemid 40544651)
27. Wei JS, Greer BT, Westermann F, et al: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 64:6883-6891, 2004 (Pubitemid 39330995)
28. Fredlund E, Ringnér M, Maris JM, et al: High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A 105:14094-14099, 2008
29. Westermann F, Muth D, Benner A, et al: Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9:R150, 2008
30. Fischer M, Oberthuer A, Brors B, et al: Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res 12:5118-5128, 2006
31. Bénard J, Raguénez G, Kauffmann A, et al: MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: A molecular portrait of stage 4S. Mol Oncol 2:261-271, 2008